Effervescent Or Pressurized Fluid Containing Patents (Class 424/43)
  • Patent number: 11319273
    Abstract: Compounds having formulas (I) to (VIII), salts thereof, or combinations thereof and pharmaceutical compositions comprising one or more these compounds are described herein for the treatment of HIV and neurodegenerative effects caused by HIV. Also provided herein are methods and a kit for inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia comprising administering the compounds having the formulas (I) to (VIII) and pharmaceutical compositions comprising the compounds having these formulas. The compounds having formulas I through VIII are curcumin analogs which are advantageously characterized as having anti-retroviral, neuroprotective, anti-glucosidase, and anti-HIV integrase properties. In one aspect, the pharmaceutical composition is delivered intranasally.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: May 3, 2022
    Assignee: HOWARD UNIVERSITY
    Inventors: Evaristus A. Nwulia, Amol Kulkarni
  • Patent number: 11291616
    Abstract: A hair care composition directed to from about 14% to about 40% of one or more surfactants; from about 0.1% to 10% of one or more surfactant soluble antidandruff agents; wherein when the hair care composition is diluted to 1.3% surfactant concentration has a ratio of surfactant diffusion coefficient to soluble agent diffusion coefficient less than 0.6 or greater than 1.4.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: April 5, 2022
    Assignee: The Procter and Gamble Company
    Inventors: Debora W Chang, Eric Scott Johnson, Robert Wayne Glenn, Jr., Todd Ryan Thompson, Allison Lynn Edwards, Michelle Lynn Carter
  • Patent number: 11154418
    Abstract: Treatment systems, methods, and apparatuses for improving the appearance of skin and other treatments are described. Aspects of the technology are directed to improving the appearance of skin by reducing a vascular structure. A non-invasive cooling device can cover and cool the vascular structure to affect the blood vessels of the vascular structure.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: October 26, 2021
    Assignee: Zeltiq Aesthetics, Inc.
    Inventor: George Frangineas, Jr.
  • Patent number: 11129783
    Abstract: The invention relates stable compact low viscosity hair care compositions comprising: from about 20 weight % to about 45 weight % total surfactant; from about 2 weight % to about 25 weight % branched anionic surfactant with a tail having an alkyl chain with 12 to 18 carbon atoms; from about 5% weight % to about 30 weight % linear anionic surfactant with a tail having an alkyl chain with 12 to 18 carbon atom; from about 0.1 weight % to about 8 weight % of a viscosity reducing agent; from about 40 weight % to about 80 weight % of water; wherein the concentrated shampoo has Ratio of Linear anionic surfactant to Branched anionic surfactant of about 0.3 to about 5, wherein the concentrated shampoo has a viscosity of less than 3000 cP at 26.5° C.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: September 28, 2021
    Assignee: The Procter and Gamble Plaza
    Inventors: Jean Jianqun Zhao, Ioannis Constantine Constantinides, Karl Shiqing Wei, Peter Herbert Koenig, Howard David Hutton, III, Robert Wayne Glenn, Jr., Xiaoru Jenny Wang, Edward Dewey Smith, III
  • Patent number: 11129896
    Abstract: Provided is a pharmaceutical formulation and a method associated therewith for treating bacterial vaginosis. The pharmaceutical formulation includes from 10 to 25 weight parts of poloxamer F127, from 0.5 to 3.0 weight parts of xanthan gum, from 70 to 90 weight parts of water, and a therapeutically effective amount of a pharmaceutical active ingredient. The pharmaceutical formulation may also include from 0.5 to 1.5 weight parts of benzyl alcohol.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: September 28, 2021
    Assignee: Trilogic Pharma LLC
    Inventors: Hemant H. Alur, James A. H. Harwick
  • Patent number: 11052127
    Abstract: The invention relates to a healthcare product comprising (i) a component selected from the group of heat shock proteins from alfalfa and heat shock protein hydrolysates from alfalfa, the product further comprising imiquimod or a pharmaceutically acceptable salt or derivative thereof. Further, the invention relates to a healthcare product for use in the prophylactic or therapeutic treatment of a skin disorder. Further, the invention relates to HSP for use for use in preventing the occurrence of a negative-side effect of a treatment with imiquimod, or alleviating such side effect.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: July 6, 2021
    Assignee: Alfa Biogene International B.V.
    Inventors: Federico G. Seifarth, Julia Lax
  • Patent number: 10984899
    Abstract: The digital personalized medicine system uses digital data to assess or diagnose symptoms of a subject to provide personalized or more appropriate therapeutic interventions and improved diagnoses. The use of prioritized questions and answers with associated feature importance can be used to assess mental function and allow a subject to be diagnosed with fewer questions, such that diagnosis can be repeated more often and allow the dosage to be adjusted more frequently. Pharmacokinetics of the subject can be estimated based on demographic data and biomarkers or measured, in order to determine a treatment plan for the subject. Also, biomarkers can be used to determine when the patient may be at risk for experiencing undesirable side effects and the treatment plan adjusted accordingly.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: April 20, 2021
    Assignee: COGNOA, INC.
    Inventor: Brent Vaughan
  • Patent number: 10925978
    Abstract: The present invention provides a novel liquid composition in the form of an emulsion or microemulsion for rectal administration comprising at least one dye, at least one emulsifier, and at least one physiologically acceptable excipient, and its use in a diagnostic endoscopic procedure of sigmoid colon and/or rectum. Preferably, said diagnostic endoscopic procedure of sigmoid colon and/or rectum is an anoscopy, a proctoscopy, a rectoscopy and/or a sigmoidoscopy.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: February 23, 2021
    Assignee: COSMO TECHNOLOGIES LIMITED
    Inventors: Luigi Moro, Enrico Frimonti, Luigi Maria Longo
  • Patent number: 10905710
    Abstract: This disclosure relates to nucleobase polymers useful for degrading GATA-3 mRNA. In certain embodiments, this disclosure relates to nucleobase polymers and nanoparticles conjugated to nucleobase polymers disclosed herein. In certain embodiments, the nucleobase polymers or nanoparticles can be used in methods of managing disorders associated with excessive GATA-3 expression in inflammatory disorders and respiratory disorders such as asthma.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: February 2, 2021
    Assignees: Emory University, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Khalid Salaita, Cherry Wongtrakool, Kornelia Galior
  • Patent number: 10849847
    Abstract: Provided are compositions and methods for treating rosacea and acne. Specifically, a gel or foam composition having a tetracycline antibiotic and uses thereof for treating rosacea and acne are provided.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: December 1, 2020
    Assignee: Foamix Pharamaceuticals Ltd.
    Inventors: Dov Tamarkin, Meir Eini, Yohan Hazot, Mitchell Shirvan, Tal Hetzroni Kedem, Rita Keynan
  • Patent number: 10839950
    Abstract: The digital personalized medicine system uses digital data to assess or diagnose symptoms of a subject to provide personalized or more appropriate therapeutic interventions and improved diagnoses. The use of prioritized questions and answers with associated feature importance can be used to assess mental function and allow a subject to be diagnosed with fewer questions, such that diagnosis can be repeated more often and allow the dosage to be adjusted more frequently. Pharmacokinetics of the subject can be estimated based on demographic data and biomarkers or measured, in order to determine a treatment plan for the subject. Also, biomarkers can be used to determine when the patient may be at risk for experiencing undesirable side effects and the treatment plan adjusted accordingly.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: November 17, 2020
    Assignee: COGNOA, INC.
    Inventor: Brent Vaughan
  • Patent number: 10799466
    Abstract: The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic such as a halogenated ether compound in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered to the subject to anesthetize the subject prior to a surgery. In certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, xenon, and mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and/or periodic administration are contemplated.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: October 13, 2020
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Phillip C. Phan, Allen W. Burton
  • Patent number: 10786459
    Abstract: A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: September 29, 2020
    Assignees: R. P. Scherer Technologies LLC, University of Mississippi
    Inventors: Sampada Bhaskar Upadhye, Ronald S. Vladyka, R.ph, Michael Andrew Repka, Jun-Bom Park, Roshan Vijay Tiwari, Hemlata Gunga Patil, Joseph Thomas Morott, Jr., Wenli Lu
  • Patent number: 10786633
    Abstract: A nebulizer utilizing a nozzle assembly includes a main conduit and an air pressure duct. The main conduit is disposed on the nebulizer and has an inner surface and an outer surface. The main conduit has an atomizing opening. The air pressure duct is disposed on one of the inner surface and the outer surface of the main conduit, and has a connecting opening connected to the sensor and a detecting opening that is exposed and adjacent to the atomizing opening. The sensor is disposed inside the nebulizer and determines a pressure change of the atomizing opening by detecting the pressure of the detecting opening. The nebulizer includes an atomizing module and a controlling module electrically connected to the atomizing module and the sensor, and the controlling module determines whether the atomizing module should be turned on based on the pressure change of the atomizing opening detected by the sensor.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: September 29, 2020
    Assignee: HCMed Innovations Co., LTD.
    Inventors: Wen-Yu Tsai, Chieh-Sheng Cheng, Chien-Shen Tsai
  • Patent number: 10782297
    Abstract: The present invention provides diagnostics for identifying and distinguishing various types of lung cancers using serum and/or bronchioalveolar lavage fluid. Signatures of secretory proteins are used to identify and distinguish lung cancers. The biomarker signatures may also be used to separate lung cancers from other inflammatory diseases, monitor progression, or assess treatment efficacy.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: September 22, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Hong Du, Cong Yan
  • Patent number: 10744135
    Abstract: The present invention belongs, in a general manner to the technological field of the pharmaceutical industry and relates, more specifically, to one or more compositions of second use to be destined for the treatment of melasma. The present invention relates to the use of substances belonging to the group of alpha-adrenergic receptor agonists, in different variable concentrations, for treating conditions of melasma upon human skin. Furthermore, the present invention discloses pharmaceutical compositions, the latter being associated or not with other compounds or methods of treatment, to be utilised for the treatment of melasma.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: August 18, 2020
    Inventor: Doris Maria Hexsel
  • Patent number: 10722465
    Abstract: An aqueous, intra-oral, transparent nanoemulsion blend in the form of a stable dispersion is provided that delivers both oil- and water-soluble components of a vitamin supplement in the desired concentrations to the cells of a mammal when orally administered. The transparent nanoemulsion blend includes at least two different bilayer water-core liposome components and at least one monolayer surfactant bound particle component. The transparent nanoemulsion blend optionally may include a micelle formed from phosphatidylcholine (PC).
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: July 28, 2020
    Assignee: Quicksilber Scientific, Inc.
    Inventors: Christopher W. Shade, Steven Tieu
  • Patent number: 10675291
    Abstract: The field of the present invention is that of fosfomycin formulations for parenteral administration, in particular for intravenous administration. Formulations of the prior art provide fosfomycin as a powder to be diluted directly prior to the administration. The aim of the invention is to provide a fosfomycin formulation for parenteral administration which is easier to produce and administer or which lowers the risk of puncture injuries for healthcare professionals and the health risks for the patients (for example due to contamination or incorrect dosages) by preventing additional processing steps. During the course of the invention, it was surprisingly shown that fosfomycin is much more stable in an aqueous solution than what is commonly assumed.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: June 9, 2020
    Inventors: Apostolos Georgopoulos, Albert Schifer, Wolfgang Rous
  • Patent number: 10650228
    Abstract: A device for detecting and recording animal behavior is provided. The device includes at least one corral that defines a contained field, the base surface of the at least one corral being sensitive to the animal's footprint. The device also includes an image capturing device that cooperates with the base surface to capture a first video frame in which at least one of a tail, body and head of the animal is illuminated by a light below the animal and a second video frame in which both a profile of a full footprint and a profile of a toe print of the animal when the animal is standing on its toes is illuminated by a light that is totally internally reflected within the base surface. A control system is arranged to control the image capturing device to capture the first and second video frames.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: May 12, 2020
    Assignees: Children's Medical Center Corporation, President and Fellows of Harvard College
    Inventors: David P. Roberson, Clifford J. Woolf, Michael T. Do, Alexander B. Wiltschko, Sandeep Robert Datta
  • Patent number: 10617688
    Abstract: The present invention pertains to the technological sector of the pharmaceutical industry and, more specifically, refers to a second use composition intended for the treatment of a dermatology condition called Poikiloderma of Civatte. The solution proposed in this document is the use of a topical composition containing any substance alone or in combination from the pharmacological group of alpha-adrenergic receptor agonists in therapeutic quantities to treat color of the lesions of Poikiloderma of Civatte. The application of this composition for the condition of Poikiloderma of Civatte results in significant improvement of the color of the skin lesions, also improving the vascular component present in this condition and can be associated with other compounds.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: April 14, 2020
    Inventor: Doris Maria Hexsel
  • Patent number: 10617419
    Abstract: A surgical buttress includes a body portion and a band disposed on each of the distal and proximal ends thereof. The surgical buttress is configured to attach to an end effector of a surgical stapling apparatus. The body portion, having perforations disposed thereon, overlies the working surface of one of the first or second jaws of the end effector. A resilient portion extends transversely beyond the side edges of the first or second jaws. Each band remains attached to the end effector following the firing thereof. The proximal band is removably attachable to a hook feature disposed on one of the first or second jaws of the end effector. The surgical buttress can be made from suitable degradable or non-degradable materials. One embodiment contemplates a detachable and disposable single use loading unit. A method of attaching the surgical buttress to a surgical apparatus is also envisioned.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: April 14, 2020
    Assignee: Covidien LP
    Inventor: Lee Olson
  • Patent number: 10532124
    Abstract: Farnesol analogs, along with their related products (e.g., treatment compositions, wipes, absorbent articles, etc.) and their methods of formation, are provided. The farnesol analog includes a hydrophilic end group (e.g., a hydroxyl end group or a carboxylic acid end group) attached to farnesol via a covalent linkage (e.g., an ester group or an ether group).
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: January 14, 2020
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: David William Koenig, Mary Kay Foegen, Corey Thomas Cunningham, Aimin He, Yang Huang
  • Patent number: 10474791
    Abstract: A method for identifying a dairy animal, the method comprising the steps of: providing an identification system comprising an imaging device and a database of stored vein patterns; obtaining at least one image of at least a portion of an udder of the dairy animal; extracting a vein pattern from the at least one image; comparing the extracted vein pattern to the database of stored vein patterns; and identifying, based on said comparison, the dairy animal in the database of stored vein patterns.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: November 12, 2019
    Assignee: ACUMEN DETECTION, INC.
    Inventors: Timothy Francis Moshier, Kenton Arthur Doctor, Stephanie A. C. Schuckers, Sean K. Banerjee, Boyang Li
  • Patent number: 10471077
    Abstract: The present invention provides a medical aerosol suspension formulation of MDI administration, comprising: a) micronized pa-agonist; b) micronized corticosteroid; c) a sib-therapextric quantity of a moisture-scavenger excipient; and d) a HFA propellant; wherein (a), (b), and (c) and their respective relative amounts are selected such that they associate to form floccules having a density substantially the same as that of the HFA propellant.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: November 12, 2019
    Assignee: Jagotec AG
    Inventors: Rudi Mueller-Walz, Lise-Marie Fueg
  • Patent number: 10471063
    Abstract: The invention provides a composition which comprises (a) a PDE3/PDE4 inhibitor which is 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a muscarinic receptor antagonist.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: November 12, 2019
    Assignee: Verona Pharma PLC
    Inventors: Michael J. A. Walker, Mario Cazzola, Luigino Calzetta
  • Patent number: 10420765
    Abstract: A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: September 24, 2019
    Assignee: ARADIGM CORPORATION
    Inventors: David C. Cipolla, James Blanchard
  • Patent number: 10406200
    Abstract: The present invention provides compositions and formulations comprising glutathione with or without thiocyanate and methods of use thereof to treat diseases and disorders in mucosal/epithelial tissue.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: September 10, 2019
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Roland R. Arnold, David C. Henke
  • Patent number: 10350164
    Abstract: A process for preparing a dry powder formulation for inhalation comprising a combination of an anti-cholinergic, a long-acting beta2-adrenoceptor agonist, and, optionally, an inhaled corticosteroid, is provided.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: July 16, 2019
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Alessandro Cavecchi, Cristiana Merusi, Fausto Pivetti, Francesca Schiaretti
  • Patent number: 10265268
    Abstract: The present invention addresses the issue of providing an external composition for screen foamers such as pump foamers, that can be safely used even when not removed after application. Provided is an external composition for screen foamers, including a non-ionic surfactant as a foaming component and, ideally, being in a soluble state.
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: April 23, 2019
    Assignee: POLA PHARMA INC.
    Inventors: Hirokazu Kobayashi, Takaaki Masuda, Tetsuya Endo, Kahori Fujii
  • Patent number: 10251460
    Abstract: An apparatus and method for providing cosmetic treatment to skin comprise one material chemically active in a solid form preferably in a tablet form and a second material which is chemically reactive with the first material so that effervescence is produced during the reaction. The chemically active materials may be activated by a user for providing cosmetic treatment to skin. The activation releases effervescence which urges granules of the reacting materials onto the skin. The size of the granules lowers during the reaction thus providing continuously refining peeling to the skin.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: April 9, 2019
    Assignee: POLLOGEN LTD.
    Inventor: Pinchas Shalev
  • Patent number: 10233209
    Abstract: Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: March 19, 2019
    Assignees: The United States of America, As represented by the Secretary, Department of Health and Human Services, The Penn State Research Foundation
    Inventors: Frank J. Gonzalez, Changtao Jiang, Cen Xie, Andrew D. Patterson, Fei Li, James B. Mitchell, Shantu Amin, Dhimant Desai
  • Patent number: 10226444
    Abstract: Composition for topical application, for use in increasing the trophism of nasal mucosa, comprising an ester of vitamin E with a carboxylic acid of formula R—COOH, in which R is an alkyl radical having 1 to 19 carbon atoms, or an alkenyl or alkynyl radical having 2 to 19 carbon atoms, and an oily vehicle; such composition can be used for the treatment of chronic atrophic rhinitis and for obtaining tissue repair of the nasal mucosa following nasal and sinus surgery.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: March 12, 2019
    Assignee: BIO.LO.GA. S.R.L.
    Inventors: Giorgio Panin, Domenico Testa, Germano Guerra
  • Patent number: 10179122
    Abstract: The present invention relates to melatonin or a pharmaceutically acceptable salt thereof for use as a medicament, the use of melatonin or a pharmaceutically acceptable salt thereof for the preparation of medicament, the use of melatonin as a food supplement and a pharmaceutical unit dosage form.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: January 15, 2019
    Inventor: Darius Rassoulian
  • Patent number: 10166180
    Abstract: Described are methods for treating a keratinized tissue condition in a subject in need thereof. The method may include providing the subject including the keratinized tissue condition. The method may include conducting one or more treatment cycles on the keratinized tissue. Each treatment cycle may include contacting the keratinized tissue with an acid-activated gas-generating composition. Each treatment cycle may include contacting the keratinized tissue with an acid composition. Each treatment cycle may include allowing the acid composition and the acid-activated gas-generating composition to react effective to generate a gas at the keratinized tissue. The one or more treatment cycles may be effective to at least partly ameliorate the keratinized tissue condition in the subject.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: January 1, 2019
    Inventor: Marty Richard Hunter
  • Patent number: 10143626
    Abstract: The present invention generally relates to a pharmaceutical dosage form and controlled release of biologically active agents, diagnostic agents, reagents, cosmetic agents, and agricultural/insecticide agents. In one embodiment, the dosage form has a substrate that forms a compartment, wherein the substrate includes at least a first piece and a second piece, wherein the first piece operably links to the second piece. The dosage form contains a drug content that is loaded into the compartment. The dosage form also has a releaser operably linked to the substrate which upon contact with water or body fluid is capable of separating the first and second piece to open the compartment and release the drug content.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: December 4, 2018
    Assignee: TRIASTEK, INC.
    Inventor: Xiaoling Li
  • Patent number: 10099246
    Abstract: Disclosed herein is an improved marking material, consisting essentially of food quality colorant (such as food coloring), and a carrier (such as water, or vegetable oil or canola oil). A method for using this material for the marking of environmental locations is also disclosed. In one form the material also comprises a propellant, all contained within a pressurized aerosol canister. The aerosol canister embodiment having a valve assembly connected to an actuator and aperture for selectively releasing the marking material. In another form, a pump-style spray bottle is utilized, and in another form a larger fluid container, pump and spray-wand type dispersal unit such as the devices commonly used in lawn and garden care, or equivalent apparatus may be utilized. In these forms, the material may consist of water-based food coloring and/or oil-based food coloring and vegetable oil depending on whether the application is dry surface or snow.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: October 16, 2018
    Inventor: Benjamin Lear Belcher
  • Patent number: 10034943
    Abstract: A pharmaceutical or cosmetic carrier for topical administration substantially consists of phosphatidylcholine, monoglyceride, fatty acid ester of C1-C3 alcohol; volatile solvent selected from ethanol and its combinations with C3-C4 alcohol and/or volatile silicone oil. Also disclosed are pharmaceutical and cosmetic compositions comprising the carrier and pharmaceutically or cosmetically active agent(s).
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: July 31, 2018
    Assignee: LIPIDOR AB
    Inventors: Bengt Herslöf, Jan Holmbäck
  • Patent number: 10015963
    Abstract: Optically isotropic, thermodynamically and chemically stable microemulsions of antimicrobials comprising of mixtures of N-undecylenoyl glycine, N-capryloyl glycine and 2-phenoxy ethanol for preservation of personal care products are described herein. They offer a broad spectrum of antimicrobial activity by inhibiting the growth of bacteria as well as fungi that can otherwise flourish in personal care products rendering them unsuitable for the use. The personal care products that can be preserved by these microemulsions of antimicrobials are, gels, serums, solutions, lotions, creams, emulsions, wet wipes and the like, containing water in varying amount.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: July 10, 2018
    Assignee: GNA Surfactants Ltd.
    Inventors: Nirmal Koshti, Bhagyesh Jagannath Sawant, Santosh Vishnu Kadam, Srinivas Uppalaswamy Pilli, Devyani Ashok Mali, Shraddha Kiran Ratnaparkhe, Pooja Vaidya Kshirsagar
  • Patent number: 10016507
    Abstract: The present invention relates to compositions and methods of inducing the self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair cells.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: July 10, 2018
    Assignee: Frequency Therapeutics, Inc.
    Inventors: Christopher Loose, Will McLean, Megan Harrison, Michael R. Jirousek
  • Patent number: 9999677
    Abstract: A wound healing composition and method for wound healing utilizing a nitrofurazone in a water soluble ointment, activated charcoal, caustic and biebrich scarlet. Applying the composition to the wound and observing epithelial healing along the sides and bottom of the wound. Stopping treatment when the epithelial tissue fills the wound.
    Type: Grant
    Filed: March 7, 2015
    Date of Patent: June 19, 2018
    Inventor: Connie D. Starns
  • Patent number: 9980981
    Abstract: The invention provides compositions and methods for delivering carbon monoxide (CO) to subjects suffering from inflammatory, cardiovascular, Sickle Cell, and other disease. The compositions are liquids, including Newtonian and non-Newtonian liquids, such as pastes, gels, foams, emulsions, and other non-gaseous compositions, in which CO is dissolved at an amount that, when administered to a patient, provides a therapeutically or prophylactically effective amount of CO to the patient. The compositions can be provided in many forms, including in bottles or cans.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: May 29, 2018
    Assignee: CHILDREN'S HOSPITAL LOS ANGELES
    Inventors: Edward D. Gomperts, Henry J. Forman
  • Patent number: 9974736
    Abstract: The invention relates to an oily composition of a non-steroidal anti-inflammatory agent (NSAIA) for parenteral administration with at least one micronized NSAIA, having an acid function and a biocompatible oily vehicle, such that said NSAIA is in the form of a free acid and said composition does not contain any added liquid agent that can solubilize said NSAIA. The invention also relates to the veterinary use thereof.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: May 22, 2018
    Assignee: VIRBAC
    Inventor: Nathalie Delhom
  • Patent number: 9949548
    Abstract: An apparatus and method for providing cosmetic treatment to skin comprise one material chemically active in a solid form preferably in a tablet form and a second material which is chemically reactive with the first material so that effervescence is produced during the reaction. The chemically active materials may be activated by a user for providing cosmetic treatment to skin. The activation releases effervescence which urges granules of the reacting materials onto the skin. The size of the granules lowers during the reaction thus providing continuously refining peeling to the skin.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: April 24, 2018
    Assignee: POLLOGEN LTD.
    Inventor: Pinchas Shalev
  • Patent number: 9849083
    Abstract: The invention provides a pharmaceutical composition for the transmucosal delivery of a statin, said composition comprising a statin and a carrier in which said statin is soluble or forms a suspension or emulsion. The invention also provides a pharmaceutical composition comprising a statin for use in inhibiting cholesterol synthesis in vivo, where in said use said composition is delivered by the transmucosal route.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: December 26, 2017
    Assignee: LondonPharma Ltd.
    Inventors: Martin James Sams, Juliet Victoria High, Paul Andrew Jamieson, Clive Booles
  • Patent number: 9801832
    Abstract: The present patent application relates to a pharmaceutical composition, characterized in that it comprises at least one active ingredient which can bring about a singlet oxygen-independent direct catalase inactivation and that the composition further comprises at least one active ingredient that leads to inactivation of catalase as a result of modulation of the nitrogen oxide or superoxide anion metabolism of the cells and subsequent singlet oxygen formation.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: October 31, 2017
    Assignee: Universitaetsklinikum Freiburg
    Inventor: Georg Bauer
  • Patent number: 9802012
    Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: October 31, 2017
    Assignee: MannKind Corporation
    Inventors: Chad C. Smutney, Benoit Adamo, Brendan F. Laurenzi, P. Spencer Kinsey
  • Patent number: 9789106
    Abstract: The present invention relates a foamable otic pharmaceutical compositions comprising oil-in water emulsions which comprise an antibiotic agent and a propellant gas. The pharmaceutical compositions are administered to the ear as foam for treating ear disorders.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: October 17, 2017
    Assignee: OTIC PHARMA LTD.
    Inventors: Evgenia Lozinsky, Yanna Galibov, Rodrigo Yelin
  • Patent number: 9750280
    Abstract: Disclosed is a pH-stabilized oral tobacco composition comprising a buffer of at least two pH stabilizing substances comprising potassium carbonate and at least one additional pH stabilizing substance that can maintain a low total drop in pH-value over prolonged time at ambient as well as refrigerated temperature, so that the freshness and shelf life of the oral tobacco composition can be improved.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: September 5, 2017
    Assignee: JT International S.A.
    Inventor: Rory Parsons
  • Patent number: 9737472
    Abstract: The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from Brachiostoma lanceolatum.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: August 22, 2017
    Assignee: ALLELE BIOTECHNOLOGY & PHARMACEUTICALS, INC.
    Inventor: Jiwu Wang
  • Patent number: RE48898
    Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: January 25, 2022
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Somasekhar Bhamidipati, Rajinder Singh, Thomas Sun, Esteban Masuda